Abstract:External exposure concentrations were conventionally employed usedto quantify toxicological effects of chemicals in their risk assessment.However, internal concentrations are more suitable for understandingthe toxicological effects and conducting risk assessment. It is necessaryfor accurate risk assessment of chemicals to predict the internalexposure of chemicals from the external exposure, and to know distributionof chemicals in different target tissues/organs (e.g. liver, kidney)of organisms. Experimental determination can hardly get high-throughputacquisition of target concentrations due to analytical limitationsand expensive cost for in vivo animal tests. Alternatively,physiologically based toxicokinetics (PBTK) models that can quantitativelypredict absorption, distribution, metabolism and excretion (ADME)processes of chemicals in biota are particularly useful. PBTK modelscould be used to predict the target concentrations, and to relatethe environmental exposure concentrations with the target concentrations. Development of PBTK models can be divided into five steps. (1)Specify the general model structure. Portal of entry, target organ,lipophilicity and metabolism of chemicals are basic factors that shouldbe considered. (2) Determine the set of ordinary differential equationsrepresenting the ADME processes of chemicals by the organism. Allof these equations are mass balance equations. (3) Define model parameters,including physiological parameters, partition coefficients, biochemicalrate constants and environment parameters. (4) Solve the ordinarydifferential equations with proper software. (5) Validate the model.Simulation results should be compared with corresponding experimentaldata to evaluate whether the model is accurate enough. Sensitivity,uncertainty and variability analysis should be performed to furtheroptimize the model. Originating as a tool for serving pharmaceutical industry, PBTKmodels are now used in risk assessment of chemicals. PBTK models canalso relate the in vivo toxicity thresholds withthe in vitro toxicity thresholds. The invitro-in vivo extrapolation can facilitate the utilizationof the vast volume of high-throughput in vitro data.Traditional in vivo tests only focus on a limitednumber of the diverse species residing within an ecosystem. PBTK modelscan provide a promising cross-species solution by establishing physiologicallyrelevant models for various species. Besides, classical indicatorsfor hazard assessment such as bioconcentration factors could be re-evaluatedby PBTK models with upgraded accuracy and details. Furthermore, itis possible to simulate the risk of chemicals that exerted on organismsover the entire lifetime of organisms with a sequence of PBTK modelsrepresenting different developmental stages of the species. The combinationof PBTK models and toxicodynamics (TD) models, i.e. PBTK/TD models,can further realize the simulation of the dynamic distribution ofxenobiotics as well as the effects simultaneously. The power of PBTK models intended for ecological risk assessmentof chemicals is yet to be fully exploited. Current PBTK models mainlyapply to chemicals of neutral states. However, the molecular structuresof many organic pollutants have carboxylic, phenolic groups, etc.Thus, these compounds can ionize under environmental pH conditions.A compound with different ionized states could possess different intakepathways. Thus, certain modifications of the mathematical form ofthe PBTK models are necessary. Another major obstacle is that thesophisticated parameters of PBTK models cannot be easily collected.Therefore, schemes for a high-throughput acquisition of the relevantparameters (e.g. quantitative structure-activity relationship models)would be highly useful. Furthermore, PBTK models should be extendedto more species of ecological importance.

Systematic Evaluation of High-Throughput PBK Modelling Strategies for the Prediction of Intravenous and Oral Pharmacokinetics in Humans

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

PBPK modeling and simulation in drug research and development

Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs

Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations

Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood–Brain Barrier and Assess Target Site Disposition

Parameter grouping and co-estimation in physiologically based kinetic models using genetic algorithms

Application of physiologically based toxicokinetics models in risk assessment of chemicals

Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example

Estimating Organ-to-Plasma Ratios in physiologically based PK modeling: a simplified approach for early drug discovery

Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development

Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®

Large scale compartmental model-based study of preclinical pharmacokinetic data and its impact on compound triaging in drug discovery

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach

Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose